Endo Health Solutions (Nasdaq: ENDP) is expected to report Q1 earnings on May 7. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Endo Health Solutions's revenues will grow 6.9% and EPS will increase 24.1%.

The average estimate for revenue is $738.5 million. On the bottom line, the average EPS estimate is $1.08.

Revenue details
 Last quarter, Endo Health Solutions tallied revenue of $801.1 million. GAAP reported sales were 0.3% lower than the prior-year quarter's $803.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $1.62. GAAP EPS were -$6.35 for Q4 against $0.30 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 61.6%, 170 basis points worse than the prior-year quarter. Operating margin was 36.8%, 650 basis points better than the prior-year quarter. Net margin was -89.4%, much worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $2.90 billion. The average EPS estimate is $4.50.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 416 members out of 438 rating the stock outperform, and 22 members rating it underperform. Among 140 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 134 give Endo Health Solutions a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Endo Health Solutions is outperform, with an average price target of $34.41.